| Names | |
|---|---|
| Preferred IUPAC name (5aR,11bS)-2-Propyl-4,5,5a,6,7,11b-hexahydrobenzo[f]thieno[2,3-c]quinoline-9,10-diol | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider |
|
| UNII | |
| |
| |
| Properties | |
| C18H21NO2S | |
| Molar mass | 315.429 g/mol |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
A-86929 is a synthetic compound that acts as a selectivedopamine receptorD1agonist.[1][2] It was developed as a possible treatment forParkinson's disease,[3] as well as for other applications such as treatment ofcocaine addiction,[4][5] but while it had reasonable efficacy in humans it also causeddyskinesias and has not been continued.[6][7] It has mainly been used as its diacetateesterprodrugadrogolide (ABT-431), which has better bioavailability.[8][9]

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |